Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Inwards

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaD J Inwards, P A Fishkin, B R LaPlant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2014
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaD J Inwards, P A Fishkin, B R LaPlant, et al.
Bone Marrow Transplantation|September 11, 2001
Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantationS A Capizzi, S Kumar, N E Huneke, et al.
Blood Cancer Journal|June 27, 2017
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)T E Witzig, B LaPlant, T M Habermann, et al.
Leukemia|June 22, 2007
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomasL F Porrata, K Ristow, T E Witzig, et al.
The American Journal of the Medical Sciences|March 1, 1995
Refractory and relapsing multiple myeloma treated by blood stem cell transplantationM A Gertz, A A Pineda, M G Chen, et al.
Cancer|January 5, 2000
Testicular lymphoma is associated with a high incidence of extranodal recurrenceR Fonseca, T M Habermann, J P Colgan, et al.
British Journal of Haematology|April 8, 1998
Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantationA Palmas, A Tefferi, J L Myers, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaD J Inwards, P A Fishkin, B R LaPlant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2014
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaD J Inwards, P A Fishkin, B R LaPlant, et al.
Bone Marrow Transplantation|September 11, 2001
Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantationS A Capizzi, S Kumar, N E Huneke, et al.
Blood Cancer Journal|June 27, 2017
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)T E Witzig, B LaPlant, T M Habermann, et al.
Leukemia|June 22, 2007
Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomasL F Porrata, K Ristow, T E Witzig, et al.
The American Journal of the Medical Sciences|March 1, 1995
Refractory and relapsing multiple myeloma treated by blood stem cell transplantationM A Gertz, A A Pineda, M G Chen, et al.
Cancer|January 5, 2000
Testicular lymphoma is associated with a high incidence of extranodal recurrenceR Fonseca, T M Habermann, J P Colgan, et al.
British Journal of Haematology|April 8, 1998
Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantationA Palmas, A Tefferi, J L Myers, et al.
Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.
Bone Marrow Transplantation|March 9, 2010
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignanciesS G Holtan, W J Hogan, M A Elliott, et al.
Pageof 6